Agustin  Melian net worth and biography

Agustin Melian Biography and Net Worth

Insider of AlloVir
Dr. Melian is AlloVir’s Chief Medical Officer & Head of Global Medical Sciences.
Prior to joining AlloVir, Dr. Melian was an SVP in both Global Clinical Development and Medical Sciences at Alexion Pharmaceuticals. During his tenure there, the company achieved record timelines across clinical development including Ultomiris (a >500 patients rare disease development program fully executed from Investigational New Drug (IND) application to filing in

Dr. Melian has a background in DNA transcription and repair. Prior to his industry work, he practiced medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. Dr. Melian graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.

What is Agustin Melian's net worth?

The estimated net worth of Agustin Melian is at least $210,367.15 as of July 2nd, 2021. Dr. Melian owns 21,665 shares of AlloVir stock worth more than $210,367 as of February 10th. This net worth estimate does not reflect any other assets that Dr. Melian may own. Learn More about Agustin Melian's net worth.

How do I contact Agustin Melian?

The corporate mailing address for Dr. Melian and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at ir@allovir.com. Learn More on Agustin Melian's contact information.

Has Agustin Melian been buying or selling shares of AlloVir?

Agustin Melian has not been actively trading shares of AlloVir during the past quarter. Most recently, Agustin Melian sold 812 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $549.93, for a transaction totalling $446,543.16. Learn More on Agustin Melian's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 46 times. They sold a total of 4,971 shares worth more than $82,278.96. The most recent insider tranaction occured on January, 23rd when General Counsel Edward Miller sold 52 shares worth more than $494.00. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 1/23/2025.

Agustin Melian Insider Trading History at AlloVir

See Full Table

Agustin Melian Buying and Selling Activity at AlloVir

This chart shows Agustin Melian's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

AlloVir Company Overview

AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.71
Low: $9.61
High: $10.16

50 Day Range

MA: $10.29
Low: $8.77
High: $12.22

2 Week Range

Now: $9.71
Low: $7.96
High: $24.15

Volume

20,504 shs

Average Volume

37,427 shs

Market Capitalization

$48.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65